Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its first-in-class cancer treatment approach. The company is developing novel treatments ...

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and ...

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due ...

Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer Research (ICR), ...

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch PSE, a new accurate blood test for ...

Merck has launched the beta version of M-Trust, a pioneering cyber-physical trust platform, at CES 2025 to tackle product ...

Angelini Ventures has co-led a €20 million Series A financing round in Neumirna Therapeutics. The financing, also led by ...